Zotepine

TargetMol
Product Code: TAR-T19680
Supplier: TargetMol
CodeSizePrice
TAR-T19680-1mg1mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19680-2mg2mg£117.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19680-5mg5mg£147.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19680-1mL1 mL * 10 mM (in DMSO)£172.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19680-10mg10mg£195.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19680-25mg25mg£322.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19680-50mg50mg£503.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19680-100mg100mg£687.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Zotepine, an antipsychotic agent, is a potent antagonist of 5-HT2A, 5-HT2C, Histamine H1, α1-adrenergic, and Dopamine D2 receptors, with Kds of 2.6 nM, 3.2 nM, 3.3 nM, 7.3 nM, and 8 nM, respectively. Zotepine is a second-generation antipsychotic with a primary use as a treatment for schizophrenia, although clinical trials have been conducted into its efficacy as an antimanic agent in patients with acute bipolar mania.
CAS:
26615-21-4
Formula:
C18H18ClNOS
Molecular Weight:
331.86
Pathway:
GPCR/G Protein; Neuroscience; Immunology/Inflammation
Purity:
0.98
SMILES:
CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12
Target:
Dopamine Receptor; 5-HT Receptor; Adrenergic Receptor; Histamine Receptor

References

1. Chan HY, Lin AS, Chen KP, Cheng JS, Chen YY, Tsai CJ. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation. J Clin Psychopharmacol. 2013 Dec;33(6):747-52. doi: 10.1097/JCP.0b013e31829e8168. PubMed PMID: 24100785. 2. Lin CC, Chiu HJ, Chen JY, Liou YJ, Wang YC, Chen TT, Bai YM. Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study. J Clin Psychopharmacol. 2013 Apr;33(2):211-4. doi: 10.1097/JCP.0b013e31828700c7. PubMed PMID: 23422395. 3. Khairkar P, Gupta N, Varma SK. Zotepine-induced convulsive seizures in a chronic case of treatment resistant paranoid schizophrenia. Indian J Pharmacol. 2013 Jan-Feb;45(1):95-7. doi: 10.4103/0253-7613.106447. PubMed PMID: 23543675; PubMed Central PMCID: PMC3608308. 4. Chen IM, Hsieh MH, Hwang TJ, Liu CC. Zotepine-related myopathy in a patient with schizophrenia. Eur J Clin Pharmacol. 2013 Mar;69(3):725-6. doi: 10.1007/s00228-012-1346-y. Epub 2012 Jul 14. PubMed PMID: 22797903.